Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ambroxol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 3/20 | 0.83 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.83 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.83 |
| ▸ | LMNA | P02545 | 2/20 | 0.83 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.83 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.83 |
| ▸ | GBA1 | P04062 | 1/20 | 0.83 |
| ▸ | CNR1 | P21554 | 1/20 | 0.83 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.83 |
| ▸ | HRH2 | P25021 | 1/20 | 0.83 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.81 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.81 |
| ▸ | TSHR | P16473 | 1/20 | 0.81 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.81 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | PDE4A | P27815 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ambroxol SCHEMBL423712 | 0.91 | CYP2D6 (1.00) | CYP2D6SLC6A4KCNH2LMNACYP1A2 | |
| Ambroxol SCHEMBL29380194 | 0.91 | CYP2D6 (1.00) | CYP2D6SLC6A4KCNH2LMNACYP1A2 | |
| Ambroxol SCHEMBL18702 | 0.91 | CYP2D6 (1.00) | CYP2D6SLC6A4KCNH2LMNACYP1A2 | |
| Ambroxol SCHEMBL28472066 | 0.91 | CYP2D6 (1.00) | CYP2D6SLC6A4KCNH2LMNACYP1A2 | |
| Ambroxol SCHEMBL7855003 | 0.91 | CYP2D6 (1.00) | CYP2D6SLC6A4KCNH2LMNACYP1A2 | |
| Ambroxol SCHEMBL6601413 | 0.90 | CYP3A4 (1.00) | CYP2D6SLC6A4KCNH2LMNACYP1A2 | |
| Ambroxol SCHEMBL99455 | 0.90 | CYP3A4 (1.00) | CYP2D6SLC6A4KCNH2LMNACYP1A2 | |
| Ambroxol SCHEMBL1648757 | 0.89 | CYP2D6 (0.94) | CYP2D6SLC6A4KCNH2LMNACYP1A2 | |
| Ambroxol SCHEMBL11533052 | 0.88 | CYP2D6 (0.87) | CYP2D6SLC6A4KCNH2LMNACYP1A2 | |
| SCHEMBL24446418 | 0.83 | CYP2D6 (0.84) | CYP2D6SLC6A4KCNH2LMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230381323-A1 | RELEASABLE CONJUGATES | FISH & RICHARDSON PC | 2023-11-30 | — | — | US | disclosed |
| US-11786599-B2 | Releasable conjugates | QUIAPEG PHARMACEUTICALS AB (SE) | 2023-10-17 | — | — | US | disclosed |
| US-20230123784-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | ASCENDIS PHARMA A/S (DK) | 2023-04-20 | — | — | US | disclosed |
| US-11559482-B2 | Biodegradable polyethylene glycol based water-insoluble hydrogels | ASCENDIS PHARMA A/S (DE) | 2023-01-24 | — | — | US | disclosed |
| EP-4011396-A1 | RELEASABLE CONJUGATES | QuiaPEG Pharmaceuticals AB (SE) | 2022-06-15 | — | — | EP | disclosed |
| EP-3592393-B1 | RELEASABLE CONJUGATES | QUIAPEG PHARMACEUTICALS AB (SE) | 2021-12-01 | — | — | EP | disclosed |
| US-11116849-B2 | Hydrogel-linked prodrugs releasing tagged drugs | ASCENDIS PHARMA A/S (DK) | 2021-09-14 | — | — | US | disclosed |
| EP-3782649-A1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | Ascendis Pharma A/S (DK) | 2021-02-24 | — | — | EP | disclosed |
| EP-2459220-B1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | ASCENDIS PHARMA AS (DK) | 2020-09-09 | — | — | EP | disclosed |
| US-10653795-B2 | — | — | 2020-05-19 | — | — | US | disclosed |
| EP-2459220-A1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | Ascendis Pharma A/S (DK) | 2012-06-06 | — | — | EP | disclosed |
| WO-2011089216-A1 | DIPEPTIDE-BASED PRODRUG LINKERS FOR ALIPHATIC AMINE-CONTAINING DRUGS | ASCENDIS PHARMA AS (DK) | 2011-07-28 | — | — | WO | disclosed |
| WO-2011012715-A1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | ASCENDIS PHARMA AS (DK) | 2011-02-03 | — | — | WO | disclosed |
| US-7122539-B2 | Nitric esters and nitrate salts of specific drugs | NICOX S.A. (FR) | 2006-10-17 | — | — | US | disclosed |
| US-6828342-B2 | Nitrate salts of Salbutamol, Cetirizine, Loratadine, Terfenadine, Emedastine, Ketotifen, Nedocromil, Ambroxol, Dextromethorphan, Dextorphan, Isoniazide, Erythromycin, and Pyrazinamide; respiratory system pathology treatment | NICOX, S.A. (FR) | 2004-12-07 | — | — | US | disclosed |
| US-20040132744-A1 | lower gastrointestinal and cardiovascular side effects; use in treatment of respiratory system disorders, as tokolitics and as antiallergics, for eye applications. | NICOX S.A. | 2004-07-08 | — | — | US | disclosed |
| US-20030028026-A1 | Nitric esters and nitrate salts of specific drugs | NICOX S.A. | 2003-02-06 | — | — | US | disclosed |
| US-6410791-B1 | SALBUTAMOL; RESPIRATORY SYSTEM DISORDERS | NICOX S.A. (FR) | 2002-06-25 | — | — | US | disclosed |
| EP-1098870-A2 | NITRIC ESTERS AND NITRATE SALTS OF SPECIFIC DRUGS | NICOX S.A. (FR) | 2001-05-16 | — | — | EP | disclosed |
| WO-2000006531-A2 | NITRIC ESTERS AND NITRATE SALTS OF SPECIFIC DRUGS | NICOX S.A. (FR) | 2000-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030028026-A1 | Nitric esters and nitrate salts of specific drugs | NOS3, NOS2, NOS1 | CYP2D6 64/4885SLC6A4 195/4885KCNH2 1722/4885 |
| US-20230123784-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | PLG, PHYKPL, PLOD3 | CYP2D6 931/4885SLC6A4 4206/4885KCNH2 4763/4885 |
| US-20040132744-A1 | lower gastrointestinal and cardiovascular side effects; use in treatment of respiratory system disorders, as tokolitics and as antiallergics, for eye applications. | PTGIS, MGST3, TNNT2 | CYP2D6 1189/4885SLC6A4 1490/4885KCNH2 633/4885 |
| US-20230381323-A1 | RELEASABLE CONJUGATES | GUSB, ABCB11, UGT2B7 | CYP2D6 55/4885SLC6A4 1369/4885KCNH2 4572/4885 |
| US-10653795-B2 | — | PTMS, MSN, CD44 | CYP2D6 108/4885SLC6A4 3089/4885KCNH2 4810/4885 |
| US-11559482-B2 | Biodegradable polyethylene glycol based water-insoluble hydrogels | PLG, PHYKPL, PLOD3 | CYP2D6 931/4885SLC6A4 4206/4885KCNH2 4763/4885 |
| US-11786599-B2 | Releasable conjugates | GUSB, ABCB11, UGT2B7 | CYP2D6 55/4885SLC6A4 1369/4885KCNH2 4572/4885 |
| US-11116849-B2 | Hydrogel-linked prodrugs releasing tagged drugs | PTMS, PGLS, PAM | CYP2D6 21/4885SLC6A4 1937/4885KCNH2 4783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.